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Abstract 
One of the problems linked to the use of acenocoumarol in therapy is the intra and interindividual variability of 
the doses necessary to obtain the desired INR; this may be due to several factors, including drug interactions. 
This is how we felt the need and the importance of undertaking this work which aims to identify the drugs most 
likely to interact with acenocoumarol and to assess the risk level of these interactions. 
This is a prospective, single-center cross-sectional study from January 01, 2017 until April 30, 2017, conducted 
at the pharmacovigilance service of the Oran EHU. In order to assess the risk level of an interaction, we used an 
interaction weighting method which allowed us to calculate the criticality indices (CI). 
The results highlighted 22 drugs at high risk of interacting with acenocoumarol of which amiodarone, 
omeprazole and diclofenac sodium are the most involved. This work was carried out with the aim of optimizing 
and securing acenocoumarol treatment. 
Keywords: Acenocoumarol; drug interactions; criticality index. 
1. Introduction  
In Algeria, acenocoumarol is the only anti-vitamin K (AVK) available. One of the problems associated with the 
use of this anticoagulant is the existence of a great intra- and inter-individual variability of the doses necessary 
to obtain the desired International Normalized Ratio (INR). Such variability in drug response depends on several 
factors, including drug interactions (AMIs). Since warfarin is the most commonly prescribed VKA worldwide, 
most VKA drug interactions found in the drug literature concerns this coumarin derivative.  
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However, the pharmacokinetics in particular the metabolism of warfarin is different from that of 
acenocoumarol, therefore these differences have a direct impact on drug interactions, especially those of a 
pharmacokinetic nature. The objective of this work is to analyze the drug prescriptions of our study population 
in order to target the drugs most at risk of interacting with acenocoumarol followed by a weighting of the level 
of risk of the interaction in s '' based on the pharmacological data (kinetics and dynamics) of drugs co-prescribed 
with acenocoumarol. 
2. Material and methods  
2.1. Type and location of the study 
This is a single-center cross-sectional prospective study running from January 01, 2017 to April 30, 2017, 
conducted at the level of the pharmacovigilance service of the EHU of Oran. 
2.2. Study population 
We included in our study patients treated with acenocoumarol for the following pathologies: embologenic heart 
disease (atrial fibrillation, mitral valve disease, valve prostheses, etc.), deep vein thrombosis, and benefiting 
from regular monitoring of the INR, some or their age, sex and associated treatments. 
Excluded from our study, patients with a history of smoking, alcoholism, patients with a diet rich in vitamin K 
and patients with poor compliance. 
2.3. Compendium of Acenocoumarol Drug Interactions 
To establish the database of drug interactions of acenocoumarol, we gathered all the bibliographic data 
concerning drugs interacting with VKA using the following repositories and drug interaction detection software: 
VIDAL expert 2016 [1], Review Prescribe 2016 [2], Thesaurus of drug interactions ANSM 2016 [3], Slockley's 
Drugs Interactions 2014 [4]. These data were used to develop the guide to drug interactions of antivitamins K. 
2.4. Collection of patient medication prescriptions 
 
Figure 1: The follow-up sheet for patients on acenocoumarol. 




The patient's drug prescriptions were collected using the follow-up sheet for patients on acenocoumarol. Figure1 
2.5. Weighting of the risk level of interactions 
In order to assess the level of risk of an interaction, a method of weighting interactions based on a model 
developed by Gschwind L et al for the prospective analysis of FMEA-type risk (analysis of failure modes of 
their effects and of their criticality) was used. This approach is based on pharmacological data (kinetics and 
dynamics) of drugs co-prescribed with acenocoumarol [5]. It consists of calculating the criticality index for each 
drug by multiplying three scores, the first score is based on the exact mechanism of the interaction, it varies 
from 1 to 10, The second score ranging from 1 to 10 concerned the frequency of occurrence of a 
supratherapeutic INR (≥6), finally the last score concerned the occurrence of a hemorrhagic accident. Drugs 
with the highest criticality indices (CI) are considered to be the drugs most at risk for bleeding or thrombotic 
complications when combined with acenocoumarol.  
3. Results and discussion 
3.1. Development of the acenocoumarol AMI database 
Our literature search on drug interactions with acenocoumarol identified 376 drugs that may interact with 
acenocoumarol. The most incriminated families were anticancer drugs, antiplatelet drugs, non-steroidal anti-
inflammatory drugs (NSAIDs), glucocorticoids (except hydrocortisone), low molecular weight heparins and 
related (curative doses and / or elderly), selective inhibitors of the reuptake of serotonin, mixed adrenergic-
serotonergic drugs, androgens, enzyme-inducing anticonvulsants, cytotoxics, fibrates, HMG-COA reductase 
inhibitors (statins), protease inhibitors boosted by ritonavir and other drugs. These interactions have been 
compiled in an Acenocoumarol Interaction Log. 
3.2. Characteristics of the study population 
Table 1: Summary table of clinical and demographic characteristics of the study population. 
Parameter Variables 
Low dose of acenocoumarol 
(≤17.5mg / week) 
n = 11 
High dose of acenocoumarol 
(> 17.5 mg / week) 
n = 29 













Size (cm) 166.72 167.36 166.44 
Weight (kg) 67.76 61.91 69.22 
Body mass index 24.19 22.13 25.04 
In our study, 40 patients treated with acenocoumarol were followed up at the EHU pharmacovigilance service in 
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Oran. The number of INRs measured was 421. INRs ≥ 4 represented (n = 40) 9.5% of total INRs, INRs ≥ 6 
represented (n = 8) 1.9% of total INRs.  
3.3. Analysis of drug prescriptions 
One hundred and forty-two prescriptions were analyzed and 340 drug interactions were identified. A total of 853 
drugs have been co-prescribed with acenocoumarol. Enoxaparin sodium and heparin calcium were not included 
in our study because they are prescribed in combination with acenocoumarol in several indications to overcome 
the latency period of acenocoumarol. 
3.4. Medicines that interact with acenocoumarol 
Based on the preestablished acenocoumarol drug interaction database, and out of a total of 68 INNs, 22 have 
been identified as potentially interacting with acenocoumarol. These drugs were co-prescribed 167 times with 
acenocoumarol representing 19.57% of the total co-prescribed drugs. The top ten co-prescribed drugs were: 
omeprazole (n = 51), amiodarone (n = 29), diclofenac sodium (n = 23), atorvastatin (n = 16), acetyl salicylic 
acid (n = 11), paracetamol (n = 10), levothyroxine (n = 10), indomethacin (n = 8), cetrizine (n = 5), 
ciprofloxacin (n = 5). Figure 1 
 
Figure 3: The drugs most co-prescribed with acenocoumarol 
 
 
3.5. Mechanism of interactions 
Of these interactions, 18% were pharmacokinetic interactions, 18% were pharmacodynamic interactions, 9% 
combined the two mechanisms and 55% were interactions whose mechanism is not well known. 
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and NSAIDs. Drugs with a pharmacokinetic interaction mechanism are represented by amiodarone, omeprazole, 
fluconazole and ciprofloxacin. Drugs which interact with both mechanisms are presented by diclofenac sodium 
and ibuprofen. Corticosteroids, antibiotics and paracetamol interacted with poorly understood mechanisms. 
Table 2 
3.6. Relationship between interaction and supratherapeutic INR 
In order to study clinically significant interactions, we looked for patients who presented with an INR≥6 
(because INR≥6 is often associated with hemorrhagic manifestations). Eight supratherapeutic INRs were 
identified, in 62.5% of them we found that there was a drug interaction with acenocoumarol. Two drugs were 
implicated: amiodarone (n = 5), omeprazole (n = 1), these were pharmacokinetic AMIs (enzymatic inhibition).  
3.7.  Relationship between interaction and INR fluctuations 
Fluctuations in INR were present in 57.7% of cases (n = 243), in 30% of them drug interactions were 
encountered. The drugs most implicated were: omeprazole (n = 36), amiodarone (n = 22), diclofenac sodium (n 
= 15), paracetamol (n = 8), indometacin (n = 8). Figure 1 
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Table 2: Classification of drugs that interact with acenocoumarol according to their mechanism of interaction 
Drug Mechanism of interaction 
Acetylsalicylic acid Pharmacodynamic interaction 
Niflumic acid Pharmacodynamic interaction 
Amiodarone Pharmacokinetic interaction 
Amoxicillin Mechanism not well known 
Atorvastatin Mechanism not well known 
Betamethasone Mechanism not well known 
Ceftriaxone Mechanism not well known 
Budesonide Mechanism not well known 
Cetrizine Pharmacodynamic interaction 
Ciprofloxacin Pharmacokinetic interaction 
Clarithromycin Mechanism not well known 
Colchicine Mechanism not well known 
Sodium diclofenac Pharmacokinetic and pharmacodynamic interaction 
Fluconazole Pharmacokinetic interaction 
Ibuprofen Pharmacokinetic and pharmacodynamic interaction 
Indomethacin Pharmacodynamic interaction 
Levothyroxine Mechanism not well known 
Omeprazole Pharmacokinetic interaction 
Paracetamol Mechanism not well known 
Prednisolone Mechanism not well known 
Tramadol Mechanism not well known 
Vancomycin  Mechanism not well known 
 
3.8. Relationship between interaction and hemorrhagic events 
In our study, bleeding events occurred in three patients, and required administration of vitamin K and red blood 
cell transfusions. Three drugs were implicated: omeprazole (n = 1), diclofenac sodium (n = 1) and amiodarone 
(n = 1). 
3.9. Assessment of the hemorrhagic risk of interactions by calculating the criticality index 
We considered drugs with a criticality index ≥10 (index chosen arbitrarily) to be the most at risk of interacting 
with acenocoumarol. Of the drugs tested, eight drugs had a criticality index ≥ 10, which are represented by the 
following drug classes: proton pump inhibitors, NSAIDs, antiplatelet agents, antifungals and amiodarone.  
Consider the mechanism of the interaction, this was in 62.5% of the cases of pharmacokinetic interaction 
(associated with a pharmacodynamic mechanism for sodium diclofenac and ibuprofen) and in 37.5% of the 
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cases of pharmacodynamic interaction. Table 3 
Table 3: Criticality indices of drugs interacting with acenocoumarol 







Amiodarone 10 8 4 320 
Omeprazole 5 3 4 60 
Sodium diclofenac 10 1 4 40 
Indomethacin 10 1 1 10 
Acetylsalicylic acid 10 1 1 10 
Ibuprofen 10 1 1 10 
Niflumic acid 10 1 1 10 
Fluconazole 10 1 1 10 
Cetrizine 5 1 1 5 
Ciprofloxacin 5 1 1 5 
Paracetamol 1 1 1 1 
Levothyroxine 1 1 1 1 
Atorvastatin 1 1 1 1 
Vancomycin 1 1 1 1 
Amoxicillin 1 1 1 1 
Tramadol 1 1 1 1 
Colchicine 1 1 1 1 
Ceftriaxone 1 1 1 1 
Prednisolone 1 1 1 1 
Betamethasone 1 1 1 1 
Clarithromycin 1 1 1 1 
Budesonide 1 1 1 1 
3.10. Discussion: 
Analysis of prescriptions from our study population revealed 340 drug interactions. 22 DCIs were responsible 
for these interactions. Indeed, two drugs have been implicated in the occurrence of a supratherapeutic INR, 
amiodarone (83%) and omeprazole (17%), this can be explained by the fact that on the one hand, amiodarone is 
a potent inhibitor of CYP2C9 the isoenzyme responsible for metabolism of the S-enantiomer of acenocoumarol 
and a large part of the R-enantiomer of acenocoumarol and omeprazole which is a potent inhibitor of CYP2C19 
the responsible isoenzyme the metabolism of part of the R-enantiomer of acenocoumarol; and on the other hand, 
these two drugs are the most co-prescribed with acenocoumarol, which increases their frequency of involvement 
in the supratherapeutic INR. Based on the risk level of interactions weighting system, amiodarone was the drug 
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with the highest risk of clinical manifestations when interacting with acenocoumarol with a criticality index CI 
= 320. This interaction has been widely described in the literature, rigorous monitoring is therefore 
recommended during the use of this combination and given the long half-life of amiodarone (20 to 100 days) 
[6], and precautions should be taken and maintained for several weeks after stopping treatment. Omeprazole 
also had a high risk of interaction with acenocoumarol with a criticality index CI = 60. Omaprazole, which is 
often co-prescribed with acenocoumarol to prevent gatro-duodenal bleeding, is a potent inhibitor of CYP2C19 
for this reason the INR should be followed closely in combination. Our results are similar to those published by 
Gschwind and al [5] which classify omeprazole with drugs at high risk of interacting with acenocoumarol. The 
observational study by Teichert and al [7] found that the risk of an increased effect of aenocoumarol when 
combined with omeprazole is less pronounced and not significant. Given the contribution of CYP2C19 only in 
R- metabolism and taking into account the short half-life of omeprazole (1 hour), it is considered that 
omeprazole can be prescribed without risk with acenocoumarol provided it is not not take them at the same time. 
The interaction between NSAIDs and acenocoumarol has been widely described in the literature, they increase 
the risk of bleeding through their ulcerative action on the gastric mucosa. Azole antifungals increased the 
hemorrhagic risk of acenocoumarol by enzymatic inhibition of CYP 2C9 and CYP 2C19, the enzymes 
responsible for the metabolism of acenocoumarol, this is in agreement with the study published by Schelleman 
and al [8] as well as study published by Becker and al [9], who found a significant increase in the INR when 
azole antifungals were combined with acenocoumarol, requiring a reduction of up to 50% of the dose of 
acenocoumarol administered according to the study made by Lozano and al [10]. Acenocoumarol does not 
increase the effect of acetylsalicylic acid but interferes with its antiplatelet action. On the other hand, in our 
study, tramadol and antibiotics were not involved in the occurrence of hemorrhagic events with acenocoumarol, 
unlike studies carried out by Penning-van beest F, and al. [11], Schelleman and al [8] and Gschwind and al [5] 
which show that these drugs are at high risk of bleeding, this can be attributed to the fact that in our case it is a 
single-center study which s 'is interested only in patients hospitalized at the EHU of Oran as well as the non-use 
of tramadol for analgesic purposes in order to avoid its interaction with acenocoumarol. 
4. Conclusion: 
Given that the clinical consequences linked to drug interactions are often unrecognized and sometimes lead to 
inappropriate therapeutic attitudes. It therefore seemed advisable to us to study the drug interactions of 
acenocoumarol in order to improve the quality of the prescription and the safety of use of acenocoumarol. 
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